Impact of an antimicrobial time-out program on antimicrobial consumption rate in hospitalized patients: a quasi-experimental study on the national antimicrobial stewardship program in Iran: Iranian antimicrobial stewardship program

TL;DR

A national antimicrobial stewardship program in Iran reduced the use of certain antibiotics and antifungals in hospitalized patients without affecting patient outcomes.

Contribution

The study demonstrates the effectiveness of an antimicrobial time-out program in reducing antimicrobial consumption in a real-world hospital setting.

Findings

The consumption of restricted antimicrobials like imipenem, linezolid, and vancomycin decreased significantly after the program.

The total cost of antimicrobial agents dropped by 22.24% following the implementation of the program.

No significant changes in patient length of stay or mortality rate were observed.

Abstract

This study evaluated the impact of the national antimicrobial stewardship program (NASP) on the consumption of antimicrobial agents.

A quasi-experimental study was conducted on hospitalized patients at a referral hospital in Tehran, Iran. We compared the antimicrobial-defined daily dose (DDD) and antimicrobial consumption index (ACI) between the third quarter of 2022 (before the implementation of NASP after the COVID-19 pandemic in October 2022) and the same timeframe in 2023, following the NASP implementation. The NASP was based on antimicrobial time-out assessment. Within 72 h of prescribing meropenem, imipenem, linezolid, vancomycin, voriconazole, caspofungin, and amphotericin B liposomal, infectious disease specialists audited the clinical and microbiological evidence of patients to assess whether it was consistent with the correct prescription.

The antimicrobial consumption rate was assessed in 13,794 and 15,030 hospitalized patients during the third quarter of 2022 and the third quarter of 2023, respectively. The mean length of hospital stay and mortality rate showed no significant differences. The consumption of all restricted antimicrobials decreased. This reduction was significant for imipenem, caspofungin, vancomycin, and linezolid. The total cost of antimicrobial agents had a 22.24% reduction after the NASP implementation (P = 0.01).

The antimicrobial time-out program was associated with a reduction in the use of antimicrobials, including imipenem, linezolid, and vancomycin and antifungals, such as caspofungin without increasing the length of stay and mortality rate. The NASP implementation can be recommended as a beneficial method for reducing the use of broad-spectrum antimicrobials.

Figures